Biological drugs are the newest wave of exciting drugs that are being developed and LSNE is a rare asset in that industry. The business provides innovative lyophilisation solutions to the pharma, healthcare & biotech industries. Backing LSNE capitalises on two of our healthcare team’s core themes: healthcare outsourcing and complexity in niche markets. Find out how we are supporting its innovation and expansion.
- Home
- News & Views
- Views
- Find out why LSNE is a rare asset in the Healthcare industry
More Views


Consumer-Tech trends
07 February 2019
Tech investing: Where disruption is an asset
07 November 2018

Duff & Phelps has a strong history of M&A. Find out how we are supporting its ambitious growth plans.
06 November 2018

Over the last 30 years tech has conquered the world...
05 November 2018

NOAH Berlin 2018: New technology and new opportunities
25 October 2018

NOAH Berlin 2018: Global growth in technology
23 October 2018